Arrevus 20logo 20png


Developing a generation of antiinfectives that leverage evolution to combat antimicrobial resistance

  • Stage Product In Development
  • Industry Biotechnology
  • Location Durham, NC, US
  • Currency USD
  • Founded August 2015
  • Employees 3
  • Incorporation Type C-corp
  • Website arrevus.com

Company Summary

Arrevus is a biotechnology company whose mission is to eliminate the threat of antibiotic resistance from clinical care through the development of Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs). Our lead DPC, ARV-1502 has successfully completed animal activity testing. ARV-1502 also has an issued US composition of matter patent that grants Arrevus full worldwide rights, all indications.


  • 9129b37e a9a1 448b 95c6 fbe045375c92
    Chief Executive Officer

    Dr. Kraus is board-certified physician (ID and IM) with more than 15 years’ experience in drug development, from Discovery (Tuberculosis Research Section, NIH), to submission (Chief Medical Officer, Nanotherapeutics) to Regulatory review (Medical Officer, Office of Antiinfective Products, FDA). He has also served on the IDSA’s Antibiotic Resistance Committee. Dr. Kraus has contributed to multiple INDs, BLAs and NDAs in infectious disease.

  • Default avatar
    Doris M. Snow, Ph.D.
    Chief Regulatory Officer

    Dr. Snow is a biologic chemist with more than 25 years’ experience in biochemistry, quality and regulatory affairs. She has advised and led the development of innovative regulatory strategies for programs including combination products (drug/device) and the FDA Animal Rule. Dr. Snow has successfully developed regulatory approval strategies for US and global markets, contributing to more 20 IND, 2 BLA, and 3 NDA-related regulatory applications.

  • Default avatar
    Robert V. House, Ph.D.
    Chief Operating Officer

    Dr. House is a parasitologist with more than 25 years’ experience in biopharmaceutical preclinical research, including basic and applied research in immunology, cytokine biology, immunotoxicology and animal disease modeling. He has evaluated the preclinical safety and efficacy of nearly 400 pharmaceutical, environmental and consumer care products and has successfully supported the acquisition of > $1B in non-dilutive government contracts.


  • Default avatar
    Prabha Fernandes, Ph.D.
    Default avatar
    Alan Baldwin
  • Default avatar
    Akshay Vaishnaw